All E-Cadherin reagents are produced in house and quality controlled, including 22 E-Cadherin Antibody, 2 E-Cadherin ELISA, 25 E-Cadherin Gene, 3 E-Cadherin IPKit, 7 E-Cadherin Lysate, 7 E-Cadherin Protein, 3 E-Cadherin qPCR. All E-Cadherin reagents are ready to use.
Recombinant E-Cadherin proteins are expressed by HEK293 Cells, Baculovirus-Insect Cells with fusion tags as C-human IgG1-Fc, C-His.
E-Cadherinantibodies are validated with different applications, which are WB, ELISA, IHC-P, IP, FCM, ICC/IF, IF, IHC-Fr, ELISA(Cap).
E-CadherincDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each E-Cadherin of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.
E-CadherinELISA Kit are quality controlled by 8 internation QC standard which guarantee every ELISA Kit with high quality.
Expression host: Baculovirus-Insect Cells
Cadherins are calcium-dependent cell adhesion proteins which preferentially interact with themselves in a homophilic manner in connecting cells, and thus may contribute to the sorting of heterogeneous cell type. E-cadherin (E-Cad), also known as CDH1 and CD324, is a calcium-dependent cell adhesion molecule the intact function of which is crucial for the establishment and maintenance of epithelial tissue polarity and structural integrity. Mutations in CDH1 occur in diffuse type gastric cancer, lobular breast cancer, and endometrial cancer. In human cancers, partial or complete loss of E-cadherin expression correlates with malignancy. During apoptosis or with calcium influx, E-Cad is cleaved by the metalloproteinase to produce fragments of about 38 kDa (E-CAD/CTF1), 33 kDa (E-CAD/CTF2) and 29 kDa (E-CAD/CTF3), respectively. E-Cad has been identified as a potent invasive suppressor, as downregulation of E-cadherin expression is involved in dysfunction of the cell-cell adhesion system, and often correlates with strong invasive potential and poor prognosis of human carcinomas.